The state of Minnesota currently has 37 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Minneapolis, Rochester, Saint Paul and Duluth.
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Care Access Research - Minneapolis, Minneapolis, Minnesota
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Total Contact Soft Cast in Diabetic Foot Ulcers
Recruiting
To determine the effectiveness, compliance, patient tolerance, ease of use and safety of total contact soft cast in diabetic foot ulcers.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetic Foot Ulcer, Diabetes Mellitus, Foot Ulcer, Foot Ulcer, Diabetic, Ulcer, Ulcer Foot, Ulcer, Leg, Ankle Ulcer
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: International Diabetes Center, Minneapolis, Minnesota
Conditions: Type 2 Diabetes
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Allina Health, Virginia Piper Cancer Institute, Coon Rapids, Minnesota +2 locations
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus
Recruiting
Nutrition guidelines state that multiple eating patterns are effective for type 2 diabetes and that therapy should be individualized. Yet many nutrition plans fail to account for interpersonal variability in blood glucose response to meals. This diminishes the ability of dietary interventions to optimize glycemic control and may lessen patient satisfaction, self--efficacy, and adherence. Continuous glucose monitoring (CGM) can facilitate behavior change in type 2 diabetes and has been associated... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Type 2 Diabetes
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Metropolitan Heart and Vascular Institute (MHVI), Coon Rapids, Minnesota +1 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
Recruiting
Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Indigestion, Diabetes Mellitus
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Recruiting
The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/28/2024
Locations: Park Nicollet International Diabetes Center, Saint Louis Park, Minnesota
Conditions: Type 2 Diabetes Treated With Insulin
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Recruiting
This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
05/28/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Healthy, Type 2 Diabetes, Obesity
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Recruiting
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experime... Read More
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
05/28/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type2diabetes
The Effects of Glucagon on Hepatic Metabolism
Recruiting
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid... Read More
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
05/28/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obesity, Type2diabetes, NAFLD
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Recruiting
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec onc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: International Diabetes Center, Minneapolis, Minnesota
Conditions: Diabetes, Type 2